Skip to main content

5 Result(s)

within Beth A. Zamboni Remove this filter

and

  1. No Access

    Article

    Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer

    Significant variability in the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin (PLD) exists. PLD undergoes clearance via the mononuclear phagocyte system (MPS). Technetium Tc 99m sulfu...

    Hugh Giovinazzo, Parag Kumar, Arif Sheikh… in Cancer Chemotherapy and Pharmacology (2016)

  2. No Access

    Article

    Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

    To investigate pharmacokinetics (PK) of encapsulated CPT-11, released CPT-11 and the active metabolite SN-38 following administration of IHL-305 and to identify factors that may influence IHL-305 PK.

    Huali Wu, Jeffrey R. Infante, Vicki L. Keedy… in European Journal of Clinical Pharmacology (2013)

  3. No Access

    Article

    Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients

    There is significant inter-patient variability in the pharmacokinetics of pegylated liposomal doxorubicin (PLD). Identification of factors affecting the pharmacokinetics of PLD would enable personalization of ...

    Ninh M. La-Beck, Beth A. Zamboni, Alberto Gabizon… in Cancer Chemotherapy and Pharmacology (2012)

  4. No Access

    Article

    Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

    The objectives of this study were to determine whether the midazolam clearance predicted docetaxel pharmacokinetics, CA-125 change, and response and to assess the impact of cytochrome P450 (CYP) 3A5 and ATP-bi...

    William C. Zamboni, Austin J. Combest… in Cancer Chemotherapy and Pharmacology (2011)

  5. No Access

    Article

    Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice

    Purpose: DB-67 is a silatecan, 7-silyl-modified camptothecin, with enhanced lipophilicity and increased blood stability of the active-lactone ring. The generation of a liposomal formulati...

    William C. Zamboni, Laura L. Jung, Sandra Strychor… in Investigational New Drugs (2008)